MS Speaks
Multiple Sclerosis => TREATMENTS => TECFIDERA (dimethyl fumarate, BG-12, Fumaderm) => Topic started by: agate on August 20, 2020, 10:33:11 am
-
From PubMed (August 20, 2020)--"Progressive multifocal leucoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients":
https://pubmed.ncbi.nlm.nih.gov/32808554/
The researchers are affiliated with the Consortium of Multiple Sclerosis Centers (CMSC) and the University of Michigan.
-
Some Biogen researchers have published a report on MS patients being treated with dimethyl fumarate who developed PML.
From Multiple Sclerosis Journal (November 10, 2022)--"Progressive multifocal leucoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate":
https://journals.sagepub.com/doi/full/10.1177/20552173221132469
-
The authors of the article in the previous post in this thread have published a correction (Multiple Sclerosis Journal, February 27, 2023):
https://journals.sagepub.com/doi/full/10.1177/20552173231160312